Exelixis
EXEL
#1574
Rank
โ‚น945.62 B
Marketcap
โ‚น3,379
Share price
2.76%
Change (1 day)
85.99%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): โ‚น182.36 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚น189.38 Billion. an increase over the revenue in the year 2023 that were of โ‚น152.36 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 โ‚น186.04 B22.11%
2023 โ‚น152.36 B14.29%
2022 โ‚น133.31 B24.82%
2021 โ‚น106.80 B47.89%
2020 โ‚น72.22 B4.65%
2019 โ‚น69.01 B15.6%
2018 โ‚น59.70 B106.64%
2017 โ‚น28.89 B122.06%
2016 โ‚น13.01 B426.67%
2015 โ‚น2.47 B55.22%
2014 โ‚น1.59 B-17.8%
2013 โ‚น1.93 B-25.48%
2012 โ‚น2.59 B-83.04%
2011 โ‚น15.32 B84.78%
2010 โ‚น8.29 B17.76%
2009 โ‚น7.04 B24.3%
2008 โ‚น5.66 B27.21%
2007 โ‚น4.45 B1.9%
2006 โ‚น4.37 B27.85%
2005 โ‚น3.41 B49.33%
2004 โ‚น2.28 B-2.45%
2003 โ‚น2.34 B10.41%
2002 โ‚น2.12 B7.42%
2001 โ‚น1.97 B71.23%
2000 โ‚น1.15 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚น3.515 T 1,756.07%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น4.188 T 2,111.48%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น5.516 T 2,812.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.217 T 2,127.14%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.918 T 1,441.20%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.756 T 3,995.59%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.249 T 2,671.75%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.89 B-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น8.23 B-95.65%๐Ÿ‡บ๐Ÿ‡ธ USA